PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
15.72%
Cash & equivalents growing 15.72% while Medical - Pharmaceuticals shows decline of -6.91%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
No Data
No Data available this quarter, please select a different quarter.
15.72%
Below half the Medical - Pharmaceuticals median of -6.46% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
77.71%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
1.23%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.70%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-0.81%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
3.86%
Below half the Medical - Pharmaceuticals median of -0.92%. Jim Chanos would question if the company faces working capital strain.
1.65%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.57%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-7.31%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-7.31%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-0.21%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
0.21%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-0.21%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
1.44%
≥ 1.5x the Medical - Pharmaceuticals median of 0.20%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
2.13%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-0.77%
Payables growth below half of Medical - Pharmaceuticals median of 1.46%. Joel Greenblatt sees more conservative payables management vs. peers.
301.49%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-39.70%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-35.74%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-6.74%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
2.09%
50-75% Medical - Pharmaceuticals median of 3.96%. Mohnish Pabrai notes fewer yoy liability expansions.
-4.77%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.22%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-3.10%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
1.53%
Above 1.5x Medical - Pharmaceuticals median of 0.94%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
3.05%
Below half Medical - Pharmaceuticals median of -1.85%. Jim Chanos suspects poor profitability or large dividend drains.
7.89%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
2.84%
Below half Medical - Pharmaceuticals median of -0.33%. Jim Chanos suspects slower net worth growth or losses vs. peers.
2.13%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
-0.21%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
57.98%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
101.01%
Above 1.5x Medical - Pharmaceuticals median 9.14%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09